Iovance Biotherapeutics, Inc. IOVA
Set alert
At close
Pre-market · Nov 3, 7:00 AM ET
- YTD
- +193.77%
- 1 year
- +311.28%
- Open
- 8.53
- Prev close
- 8.48
- Mkt cap
- 3.63B
- Vol
- 21.05M
- Avg vol
- 17.36M
- EPS
- -0.69
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.66
- High
- 8.56
- Forward P/E
- -40.97
- Beta
- 0.84
- Short ratio
- 3.26
- Inst. own
- 70.74%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 11.37
- 200-d avg
- 5.84
- 1y target
- 14.20
5D chart
Signals (134)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 3:45 PM | 15 hours ago |
| MACD: Buy Signal | Nov 2, 3:45 PM | 15 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 15 hours ago |
| MACD: Sell Signal | Nov 2, 3:35 PM | 15 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 15 hours ago |
| SMA: Bullish | Nov 2, 2:45 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 2:35 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 2:15 PM | 16 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 2:10 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 1:25 PM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 1:15 PM | 17 hours ago |
| SMA: Bearish | Nov 2, 1:00 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 11:50 AM | 19 hours ago |
| SMA: Bullish | Nov 2, 11:20 AM | 19 hours ago |
| MACD: Buy Signal | Nov 2, 11:05 AM | 19 hours ago |
| RSI: Oversold | Nov 2, 10:30 AM | 20 hours ago |
| SMA: Bearish | Nov 2, 10:25 AM | 20 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 20 hours ago |
| RSI: Oversold | Nov 2, 10:15 AM | 20 hours ago |
Newest 20 of 134.
News
17 hours ago zacks.com
Iovance Gears Up to Report Q3 Earnings: Here's What to Expect
IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.
4 days ago benzinga.com
Crude Oil Moves Lower; Caterpillar Shares Fall Following Q3 Results
U.S. stocks fell Thursday, led by a 9% Caterpillar drop; Porch, Teladoc and Crocs surged, while oil, gold and silver declined.
4 days ago seekingalpha.com
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript
4 days ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…
4 days ago marketbeat.com
Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing
Iovance Biotherapeutics NASDAQ: IOVA reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining…
4 days ago zacks.com
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
-
5 days ago benzinga.com
Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results
IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027KRAS Wild-Type Subgroup…
5 days ago globenewswire.com
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned…
5 days ago globenewswire.com
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…
6 days ago zacks.com
Best Momentum Stocks to Buy for October 27th
IOVA, MEI and PRMRF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27th, 2026.
6 days ago zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
1 week ago zacks.com
New Strong Buy Stocks for October 27th
NTSK, PRMRF, IOVA, CAPL and MEI have been added to the Zacks Rank #1 (Strong Buy) List on October 27th, 2026.
1 week ago globenewswire.com
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal…
-
1 week ago benzinga.com
Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026Unprecedented Efficacy in Both…
-
1 week ago benzinga.com
Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 AnalysisMedian Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-upOral…
-
2 weeks ago benzinga.com
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.
3 weeks ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 weeks ago benzinga.com
Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11
Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.
4 weeks ago benzinga.com
Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call
Iovance Biotherapeutics (NASDAQ:IOVA) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
4 weeks ago benzinga.com
Top 3 Health Care Stocks That May Collapse In Q4
Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.